

**AMENDMENTS TO THE CLAIMS**

Please amend the claims as follows.

1. – 5. (Cancelled).

6. (Currently Amended) A pharmaceutical composition, comprising:

- (a) an antagonist of hLRTM4 protein, hLRTM4 gene[[,]] or hLRTM4 gene transcript, wherein the hLRTM4 protein has a sequence of SEQ ID NO: 2 and the hLRTM4 gene has [[a]] the sequence of SEQ ID NO: 1, wherein the antagonist is an antibody or a polynucleotide having a contiguous fragment of at least [[15]] 30 bases that hybridize to the hLRTM4 gene or the hLRTM4 gene transcript; and
- (b) a pharmaceutically acceptable vehicle, diluent or carrier.

7. (Currently Amended) The composition of claim 6, wherein the polynucleotide is at least one selected from the group consisting of: (i) an antisense polynucleotide for the hLRTM4 gene transcript, and (ii) a small interfering RNA for the hLRTM4 gene transcript.

8. – 16. (Cancelled).

17. (Currently Amended) The composition of claim 7, wherein the antagonist is the antisense polynucleotide, wherein the antisense polynucleotide has a contiguous fragment of at least 50 bases that hybridize to the hLRTM4 gene transcript.

18. (Currently Amended) The composition of claim 7, wherein the antagonist is the antisense polynucleotide, wherein the antisense polynucleotide has a contiguous fragment of at least 100 bases that hybridize to the hLRTM4 gene transcript.

19. (New) The composition of claim 6, wherein the polynucleotide is included in an expression vector.

20. (New) A method of treating a carcinoma, comprising administering to a subject the composition of claim 6.
21. (New) The method of claim 20, wherein the carcinoma is hepatoma, gastric adenocarcinoma or stomach adenocarcinoma.